152 related articles for article (PubMed ID: 9044469)
1. Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency--three-year follow-up.
Schwaiblmair M; Vogelmeier C; Fruhmann G
Respiration; 1997; 64(1):10-5. PubMed ID: 9044469
[TBL] [Abstract][Full Text] [Related]
2. Alpha-1-antitrypsin and other proteinase inhibitors.
Miravitlles M
Curr Opin Pharmacol; 2012 Jun; 12(3):309-14. PubMed ID: 22365503
[TBL] [Abstract][Full Text] [Related]
3. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
4. [Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin].
Wencker M; Banik N; Buhl R; Seidel R; Konietzko N
Pneumologie; 1998 Oct; 52(10):545-52. PubMed ID: 9847632
[TBL] [Abstract][Full Text] [Related]
5. Alpha-1 antitrypsin augmentation therapy.
Wewers MD; Crystal RG
COPD; 2013 Mar; 10 Suppl 1():64-7. PubMed ID: 23527997
[TBL] [Abstract][Full Text] [Related]
6. Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease.
Chiuchiolo MJ; Crystal RG
Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4(Suppl 4):S352-69. PubMed ID: 27564673
[TBL] [Abstract][Full Text] [Related]
7. [Expert statement for augmentation therapy in patients with alpha-1 antitrypsin deficiency].
Köhnlein T; Schmidt-Scherzer K; Greulich T; Bals R
Pneumologie; 2014 Jul; 68(7):492-5. PubMed ID: 25006842
[TBL] [Abstract][Full Text] [Related]
8. Intravenous alpha-1-antitrypsin replacement therapy: case report after one year of treatment.
Ward AC; Keogh BA
Ir J Med Sci; 1997; 166(1):7-9. PubMed ID: 9057422
[TBL] [Abstract][Full Text] [Related]
9. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).
McElvaney NG; Burdon J; Holmes M; Glanville A; Wark PA; Thompson PJ; Hernandez P; Chlumsky J; Teschler H; Ficker JH; Seersholm N; Altraja A; Mäkitaro R; Chorostowska-Wynimko J; Sanak M; Stoicescu PI; Piitulainen E; Vit O; Wencker M; Tortorici MA; Fries M; Edelman JM; Chapman KR;
Lancet Respir Med; 2017 Jan; 5(1):51-60. PubMed ID: 27916480
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group.
Wencker M; Banik N; Buhl R; Seidel R; Konietzko N
Eur Respir J; 1998 Feb; 11(2):428-33. PubMed ID: 9551749
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough.
Balbi B; Ferrarotti I; Miravitlles M
Eur Respir J; 2016 Jan; 47(1):35-8. PubMed ID: 26721962
[No Abstract] [Full Text] [Related]
13. Randomized, Placebo-Controlled Trials in Alpha-1 Antitrypsin Deficiency.
Sandhaus RA
Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S370-3. PubMed ID: 27564674
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of replacement therapy in emphysema caused by alpha 1-antitrypsin deficiency].
Miravitlles M; Vidal R; Torrella M; Bofill JM; Cotrina M; de Gracia J
Arch Bronconeumol; 1994 Dec; 30(10):479-84. PubMed ID: 7827760
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation after 2 years of substitutive treatment of PiZZ emphysema with alpha-1 antitrypsin. 9 cases].
Carles P; Constans J; Pujazon MC; Arnaud J; Lauque D; Goudemand M
Presse Med; 1990 Mar; 19(11):514-8. PubMed ID: 2138750
[TBL] [Abstract][Full Text] [Related]
16. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.
Lieberman J
Chest; 2000 Nov; 118(5):1480-5. PubMed ID: 11083705
[TBL] [Abstract][Full Text] [Related]
17. Aralast: an alpha 1-protease inhibitor for the treatment of alpha-antitrypsin deficiency.
Mordwinkin NM; Louie SG
Expert Opin Pharmacother; 2007 Oct; 8(15):2609-14. PubMed ID: 17931094
[TBL] [Abstract][Full Text] [Related]
18. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.
Tonelli AR; Brantly ML
Ther Adv Respir Dis; 2010 Oct; 4(5):289-312. PubMed ID: 20650978
[TBL] [Abstract][Full Text] [Related]
19. [Prospective evaluation of clinical parameters of AAT patients with i. v. prolastin therapy in a homecare setting].
Wilke A; Grohé C
Pneumologie; 2013 Oct; 67(10):545-50. PubMed ID: 23999697
[TBL] [Abstract][Full Text] [Related]
20. Alpha-1 antitrypsin: now available, but do we need it?
Russi EW
Swiss Med Wkly; 2008 Apr; 138(13-14):191-6. PubMed ID: 18389391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
